Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV Infection documented CD4+ count within the last 30 days (or drawn with screening labs)~* Currently on a stable 3-drug HAART regimen including 2 NRTIs for \> 6 month viral load (VL) \< 50/mm3 for \> 6 months, last within the last 30 days (or drawn with screening labs)~* Partial immune responder or immune non-responder~* Age \> 18 years~* Labs (drawn at screening)~* Alanine transaminase (ALT) \< 5 X the upper limit of normal (ULN)~* Total bili \< 2 X ULN~* Creatinine \< 2.0 mg/dL~Exclusion Criteria:~* Prior therapy with Kaletra~* Known hypersensitivity to Ritonavir~* Therapy the drugs with potential serious drug interactions: flecainide, propafenone, astemizole, terfenadine, rifampin, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, pimozide, lovastatin, simvastatin, midazolam, triazolam, and St. John's wart.~* Pregnancy; breast feeding~* Current malignancy requiring CT~* Use of systemic corticosteroids, immunosuppressive, or cytotoxic agents within the last 45 days~* Fever and/or evidence of an active infectious complication~* Currently in another interventional clinical trial~* Receiving Interleukin-2 (IL-2) or any other cytokine or growth factor~* Enrollment in another interventional clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Kaletra + Current Dual NRTI Backbone (Type: EXPERIMENTAL): Patients in this arm received Kaletra in addition to their current Dual NRTI Backbone.
- Current Regimen (Type: ACTIVE_COMPARATOR): Patients in this study arm continued their current regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).